Literature DB >> 9131006

Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis.

P N Baird1, P J Simmons.   

Abstract

The Wilms tumor suppressor gene (WT1) is mutated in a number of cases of Wilms' tumor as well as in mesothelioma and leukemia. It encodes a transcription factor derived from any one of four alternate transcripts. WT1 has a restricted pattern of expression within the body and within the hemopoietic system its expression is limited to primitive leukemias and a number of leukemic cell lines. Given the overexpression of WT1 in leukemias, we have addressed the question of whether this gene is expressed within the normal hemopoietic system. Mononuclear bone marrow (BM) cells obtained from normal donors were separated by fluorescence-activated cell sorting (FACS) into "primitive" (CD34+) and "mature" (CD34-) cell populations. Total RNA extracted from these cells was subjected to reverse transcriptase polymerase chain reaction (RT-PCR) using primers based on the WT1 sequence, to examine the expression of this gene within the hemopoietic system. Phenotypic purity of cells was guaranteed by performing single-cell sorting followed by RT-PCR to define the precise cellular phenotypes that express WT1. Expression of WT1 was detected in cells bearing the CD34+ phenotype but not in those cells lacking expression of CD34. In addition, single-cell analysis revealed that expression of WT1 occurred in the candidate stem cell-containing population of hemopoietic cells which have the phenotype CD34+ CD38-. Moreover, the single-cell RT-PCR analysis also demonstrated that differential expression of alternate transcripts of WT1 occurs between hemopoietic progenitor cells with the same phenotype. In conclusion, expression of WT1 is limited to early progenitors of the blood system, which suggests that this gene plays a critical role in hemopoietic development.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131006

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  26 in total

Review 1.  The possible role and application of WT1 in human leukemia.

Authors:  Z Chen
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

2.  Prognostic implications of mutations and expression of the Wilms tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia.

Authors:  Sandra Heesch; Nicola Goekbuget; Andrea Stroux; Jutta Ortiz Tanchez; Cornelia Schlee; Thomas Burmeister; Stefan Schwartz; Olga Blau; Ulrich Keilholz; Antonia Busse; Dieter Hoelzer; Eckhard Thiel; Wolf-Karsten Hofmann; Claudia D Baldus
Journal:  Haematologica       Date:  2010-04-30       Impact factor: 9.941

Review 3.  Role of the Wilms' tumour transcription factor, Wt1, in blood vessel formation.

Authors:  Holger Scholz; Kay-Dietrich Wagner; Nicole Wagner
Journal:  Pflugers Arch       Date:  2008-12-04       Impact factor: 3.657

4.  The transcriptional activity of WT1 gene promoter and enhancer in cell lines with diverse tissue origin.

Authors:  Shaoyan Hu; Zixing Chen; Weiying Gu; Ruihua Chen; Ye Zhao; Jiannong Cen
Journal:  Int J Hematol       Date:  2008-05-16       Impact factor: 2.490

Review 5.  Exploiting T cell receptor genes for cancer immunotherapy.

Authors:  S Xue; R Gillmore; A Downs; A Tsallios; A Holler; L Gao; V Wong; E Morris; H J Stauss
Journal:  Clin Exp Immunol       Date:  2005-02       Impact factor: 4.330

6.  Effects of bufalin on up-regulating methylation of Wilm's tumor 1 gene in human erythroid leukemic cells.

Authors:  Li-Pei Wang; Yan-Na Zhao; Xin Sun; Rui-Lan Gao
Journal:  Chin J Integr Med       Date:  2017-04-01       Impact factor: 1.978

Review 7.  Re-adapting T cells for cancer therapy: from mouse models to clinical trials.

Authors:  Ingunn M Stromnes; Thomas M Schmitt; Aude G Chapuis; Sunil R Hingorani; Philip D Greenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

8.  Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.

Authors:  Aude G Chapuis; Gunnar B Ragnarsson; Hieu N Nguyen; Colette N Chaney; Jeffrey S Pufnock; Thomas M Schmitt; Natalie Duerkopp; Ilana M Roberts; Galina L Pogosov; William Y Ho; Sebastian Ochsenreither; Matthias Wölfl; Merav Bar; Jerald P Radich; Cassian Yee; Philip D Greenberg
Journal:  Sci Transl Med       Date:  2013-02-27       Impact factor: 17.956

9.  Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.

Authors:  Takuya Osada; Christopher Y Woo; Matthew McKinney; Xiao Yi Yang; Gangjun Lei; Heather G Labreche; Zachary C Hartman; Donna Niedzwiecki; Nelson Chao; Andrea Amalfitano; Michael A Morse; H Kim Lyerly; Timothy M Clay
Journal:  Clin Cancer Res       Date:  2009-04-07       Impact factor: 12.531

10.  The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy.

Authors:  Lesley A Simpson; Emily A Burwell; Kida A Thompson; Samira Shahnaz; Allen R Chen; David M Loeb
Journal:  Blood       Date:  2006-02-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.